Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Literature DB >> 6236748

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii.

Abstract

The activities of ciprofloxacin and norfloxacin against 100 mycobacteria isolates were studied in vitro by the 1% standard proportion method. Ciprofloxacin was more active against M. tuberculosis and M. fortuitum with MICs of 1.0 and 0.25 microgram/ml, respectively, against 90% of isolates; norfloxacin had MICs of 8.0 and 2.0 micrograms/ml, respectively, against 90% of isolates.

Entities: Chemical Species

Mesh：

Substances：

Year: 1984 PMID： 6236748 PMCID： PMC179925 DOI： 10.1128/AAC.26.1.94

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

Review 1. Nontuberculous mycobacteria and associated diseases.

Authors: E Wolinsky
Journal: Am Rev Respir Dis Date: 1979-01

2. Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors: M Y Khan; Y Siddiqui; R P Gruninger
Journal: Antimicrob Agents Chemother Date: 1981-08 Impact factor: 5.191

3. In vitro susceptibility of Mycobacterium fortuitum to cefoxitin.

Authors: M H Cynamon; A Patapow
Journal: Antimicrob Agents Chemother Date: 1981-01 Impact factor: 5.191

4. Long-term results of medical treatment in Mycobacterium intracellulare infection.

Authors: A K Dutt; W W Stead
Journal: Am J Med Date: 1979-09 Impact factor: 4.965

5. Identification of clinical isolates of mycobacteria with gas-liquid chromatography alone.

Authors: P A Tisdall; G D Roberts; J P Anhalt
Journal: J Clin Microbiol Date: 1979-10 Impact factor: 5.948

6. Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents.

Authors: H H Gadebusch; D L Shungu; E Weinberg; S K Chung
Journal: Infection Date: 1982-01 Impact factor: 3.553

7. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei.

Authors: R J Wallace; D B Jones; K Wiss
Journal: Rev Infect Dis Date: 1981 Sep-Oct

8. Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

Authors: R J Wallace; J R Dalovisio; G A Pankey
Journal: Antimicrob Agents Chemother Date: 1979-11 Impact factor: 5.191

9. In vitro antibacterial activity of norfloxacin (MK-0366).

Authors: A King; C Warren; K Shannon; I Phillips
Journal: Antimicrob Agents Chemother Date: 1982-04 Impact factor: 5.191

10. In vitro susceptiiblity of Mycobacterium fortuitum and Mycobacterium chelonei to amikacin.

Authors: J R Dalovisio; G A Pankey
Journal: J Infect Dis Date: 1978-03 Impact factor: 5.226

42 in total

1. Multicenter laboratory validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media.

Authors: G E Pfyffer; D A Bonato; A Ebrahimzadeh; W Gross; J Hotaling; J Kornblum; A Laszlo; G Roberts; M Salfinger; F Wittwer; S Siddiqi
Journal: J Clin Microbiol Date: 1999-10 Impact factor: 5.948

2. Efficacies of liposome-encapsulated streptomycin and ciprofloxacin against Mycobacterium avium-M. intracellulare complex infections in human peripheral blood monocyte/macrophages.

Authors: S Majumdar; D Flasher; D S Friend; P Nassos; D Yajko; W K Hadley; N Düzgüneş
Journal: Antimicrob Agents Chemother Date: 1992-12 Impact factor: 5.191

3. Environmental metabolites of fluoroquinolones: synthesis, fractionation and toxicological assessment of some biologically active metabolites of ciprofloxacin.

Authors: Gareth Lewis; Albert Juhasz; Euan Smith
Journal: Environ Sci Pollut Res Int Date: 2012-02-04 Impact factor: 4.223

4. Mycobacterium paraffinicum causing symptomatic pulmonary infection.

Authors: Austin W Chan; Sarah Kabbani; Gerald Staton; Colleen S Kraft
Journal: J Clin Microbiol Date: 2014-01-22 Impact factor: 5.948

5. Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in mice.

Authors: J Conley; H Yang; T Wilson; K Blasetti; V Di Ninno; G Schnell; J P Wong
Journal: Antimicrob Agents Chemother Date: 1997-06 Impact factor: 5.191

Review 6. Mycobacteria and the new quinolones.

Authors: D C Leysen; A Haemers; S R Pattyn
Journal: Antimicrob Agents Chemother Date: 1989-01 Impact factor: 5.191

7. In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae.

Authors: P Hohl; M Salfinger; F M Kafader
Journal: Eur J Clin Microbiol Date: 1987-08 Impact factor: 3.267

8. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors: J S Wolfson; D C Hooper
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

9. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.

Authors: R J Wallace; G Bedsole; G Sumter; C V Sanders; L C Steele; B A Brown; J Smith; D R Graham
Journal: Antimicrob Agents Chemother Date: 1990-01 Impact factor: 5.191

10. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.

Authors: L B Heifets; P J Lindholm-Levy
Journal: Antimicrob Agents Chemother Date: 1990-05 Impact factor: 5.191